Connect your AI

Opus Genetics IRD Change in Other Assets

Change in Other Assets at other companies

MeiraGTx Holdings plcMGTX

-$1.28M—

4D Molecular TherapeuticsFDMT

$670K-75.9%

Opko HealthOPK

-$6.97M-155%

Kodiak Sciences IncKOD

$975K+3,582%

RegenxbioRGNX

$900K+189%

Prime MedicinePRME

-$1.22M-255%

Other financials

Income statement

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

Operating cash flow-$12.7M-41.5%

Valuation

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Opus Genetics's change in other assets?: Opus Genetics (IRD) reported change in other assets of $2.14M in Q1 2026.
How has Opus Genetics's change in other assets changed year-over-year?: Opus Genetics's change in other assets increased by 147.3% year-over-year, from $865K to $2.14M.
What does change in other assets mean?: Change in miscellaneous assets affecting operating cash flow.